StockData

TFA Therapeutics, Inc. (RAJAF) stock

RAJAFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on May 15, 2026Score 7/30
$9.18+0.00 (0.00%)

Close on Oct 16, 2026Market cap –P/E –Yield –

TFA Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

TFA Therapeutics's ebitda for the twelve months ending Dec 31, 2023 was $284.59K. For fiscal 2023 it was $284.59K.

Annual ebitda

PeriodPeriod endValueChange
FY2023Dec 31, 2023$284.59K–
FY2022Dec 31, 2022-$390.63K-1408.6%
FY2021Dec 31, 2021$29.85K–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023$176.17K–

More TFA Therapeutics figures

See a number that looks wrong?